AbbVie Inc.

NYSE

Market Cap.

332.73B

Avg. Volume

7.62M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about AbbVie Inc.

AbbVie Inc. News

AbbVie Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
abbvie.com

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. Earnings & Revenue

AbbVie Inc. Financials

Table Compare

Compare ABBV metrics with:

   

Earnings & Growth

ABBV

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ABBV

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ABBV

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ABBV

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

AbbVie Inc. Income

AbbVie Inc. Balance Sheet

AbbVie Inc. Cash Flow

AbbVie Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

AbbVie Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

6.3800

Payment DateDividendFrequency
2025-05-151.64Quarterly
2025-02-141.64Quarterly
2024-11-151.55Quarterly
2024-08-151.55Quarterly
2024-05-151.55Quarterly

AbbVie Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

AbbVie Inc. Executives

NameRole
Mr. Richard A. GonzalezExecutive Chairman
Mr. Robert A. Michael CPAChief Executive Officer & Director
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer
Mr. Timothy J. RichmondExecutive Vice President & Chief Human Resources Officer
NameRoleGenderDate of BirthPay
Mr. Richard A. GonzalezExecutive ChairmanMale19548.06M
Mr. Robert A. Michael CPAChief Executive Officer & DirectorMale19706.68M
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial OfficerMale19695M
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer19634.07M
Mr. Timothy J. RichmondExecutive Vice President & Chief Human Resources OfficerMale19663.84M

AbbVie Inc. Insider Trades

Date31 Mar
NameAlpern Robert J
RoleDirector
TransactionAcquired
TypeA-Award
Shares35
Date31 Mar
NameGONZALEZ RICHARD A
RoleDirector
TransactionDisposed
TypeG-Gift
Shares2450
Date31 Mar
NameRAPP EDWARD J
RoleDirector
TransactionAcquired
TypeA-Award
Shares155
Date31 Mar
NameQuaggin Susan E
RoleDirector
TransactionAcquired
TypeA-Award
Shares71
Date31 Mar
NameStewart Jeffrey Ryan
RoleEVP, CHIEF COMMERCIAL OFFICER
TransactionAcquired
TypeM-Exempt
Shares25700
DateNameRoleTransactionTypeShares
31 MarAlpern Robert JDirectorAcquiredA-Award35
31 MarGONZALEZ RICHARD ADirectorDisposedG-Gift2450
31 MarRAPP EDWARD JDirectorAcquiredA-Award155
31 MarQuaggin Susan EDirectorAcquiredA-Award71
31 MarStewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERAcquiredM-Exempt25700

Discover More

Streamlined Academy

AbbVie Inc.

NYSE

Market Cap.

332.73B

Avg. Volume

7.62M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AbbVie Inc. News

AbbVie Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

AbbVie Inc. Earnings & Revenue

AbbVie Inc. Income

AbbVie Inc. Balance Sheet

AbbVie Inc. Cash Flow

AbbVie Inc. Financials Over Time

AbbVie Inc. Executives

NameRole
Mr. Richard A. GonzalezExecutive Chairman
Mr. Robert A. Michael CPAChief Executive Officer & Director
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer
Mr. Timothy J. RichmondExecutive Vice President & Chief Human Resources Officer
NameRoleGenderDate of BirthPay
Mr. Richard A. GonzalezExecutive ChairmanMale19548.06M
Mr. Robert A. Michael CPAChief Executive Officer & DirectorMale19706.68M
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial OfficerMale19695M
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer19634.07M
Mr. Timothy J. RichmondExecutive Vice President & Chief Human Resources OfficerMale19663.84M

AbbVie Inc. Insider Trades

Date31 Mar
NameAlpern Robert J
RoleDirector
TransactionAcquired
TypeA-Award
Shares35
Date31 Mar
NameGONZALEZ RICHARD A
RoleDirector
TransactionDisposed
TypeG-Gift
Shares2450
Date31 Mar
NameRAPP EDWARD J
RoleDirector
TransactionAcquired
TypeA-Award
Shares155
Date31 Mar
NameQuaggin Susan E
RoleDirector
TransactionAcquired
TypeA-Award
Shares71
Date31 Mar
NameStewart Jeffrey Ryan
RoleEVP, CHIEF COMMERCIAL OFFICER
TransactionAcquired
TypeM-Exempt
Shares25700
DateNameRoleTransactionTypeShares
31 MarAlpern Robert JDirectorAcquiredA-Award35
31 MarGONZALEZ RICHARD ADirectorDisposedG-Gift2450
31 MarRAPP EDWARD JDirectorAcquiredA-Award155
31 MarQuaggin Susan EDirectorAcquiredA-Award71
31 MarStewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERAcquiredM-Exempt25700

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
abbvie.com

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about AbbVie Inc.

AbbVie Inc. Financials

Table Compare

Compare ABBV metrics with:

   

Earnings & Growth

ABBV

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ABBV

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ABBV

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ABBV

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

AbbVie Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

6.3800

Payment DateDividendFrequency
2025-05-151.64Quarterly
2025-02-141.64Quarterly
2024-11-151.55Quarterly
2024-08-151.55Quarterly
2024-05-151.55Quarterly

AbbVie Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)